7:13 am ET May 18, 2020 (Dow Jones)
Chembio Diagnostics Inc. said Monday it has signed a multi-year, non-exclusive agreement with Thermo Fisher Scientific's health-care channel to distribute Chembio's DPP Covid-19 System in the U.S.
Chembio said the DPP Covid-19 System is a rapid serological test and analyzer that provides numerical readings for both IgM and IgG antibody levels within 15 minutes from a finger stick drop of blood. The system can include either Chembio's Micro Reader 1 or Micro Reader 2 analyzer.
Chembio shares rose 10% to $13.35 in premarket trading.
Rayank
Recent CEMI News
- Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer • PR Newswire (US) • 10/17/2023 09:00:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM